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Measurement variabilityThere is a drive toward the mandated lowering and reporting of selected toxicants in tobacco smoke.
Several studies have quantiﬁed the mainstream cigarette emissions of toxicants, providing benchmark
levels. Few, however, have examined how measured toxicant levels within a single product vary over
time due to natural variation in the tobacco, manufacturing and measurement. In a single centre analysis,
key toxicants were measured in the tobacco blend and smoke of 3R4F reference cigarette and three com-
mercial products, each sampled monthly for 10 months. For most analytes, monthly variation was low
(coefﬁcient of variation <15%); but higher (P20%) for some compounds present at low (ppb) levels.
Reporting toxicant emissions as a ratio to nicotine increased the monthly variation of the 9 analytes pro-
posed for mandated lowering, by 1–2 percentage points. Variation in toxicant levels was generally 1.5–
1.7-fold higher in commercial cigarettes compared with 3R4F over the 10-month period, but increased up
to 3.5-fold for analytes measured at ppb level. The potential error (2CV) associated with single-point-in-
time sampling averaged 20%. Together, these data demonstrate that measurement of emissions from
commercial cigarettes is associated with considerable variation for low-level toxicants. This variation
would increase if the analyses were conducted in more than one laboratory.
 2015 The Authors. Published by Elsevier Inc. This is an openaccess article under the CCBY license (http://
creativecommons.org/licenses/by/4.0/).1. Introduction
Since 2000, cigarette smoke toxicants have slowly developed
into a global regulatory issue. Starting with the mandated mea-
surement and reporting of toxicant emissions from cigarettes in
Canada (Health Canada, 2000) and Brazil (Brazil Resolution,
2007), the requirement to measure and report emissions has
spread to other countries. Regulatory reporting may also include
measurement of speciﬁc compounds in the cigarette tobacco ﬁller
blend and reporting of cigarette physical attributes.
In the United States, the Food and Drug Administration (FDA)
has published a list of 93 harmful and potentially harmful con-
stituents (HPHCs) in tobacco products and tobacco smoke (FDA,2012a) and issued draft guidance on the reporting of an abbreviat-
ed list of 24 HPHCs, 18 in mainstream cigarette smoke and 6 in the
cigarette ﬁller blend, for which analytical protocols are well estab-
lished and widely available although currently not standardised
(Table 1) (FDA, 2012b). The FDA has also introduced a pre-market
approval process, wherein toxicant emissions from cigarettes are
evaluated (among other information) before permission is granted
to market new tobacco products. This legislation, embodied in the
US Family Smoking Prevention and Tobacco Control Act, also
empowers the FDA to enact toxicant reduction strategies, although
they have yet to do so (US, 2009).
The World Health Organization (WHO) Study Group on Tobacco
Product Regulation (TobReg), composed of leading public health
scientists, has been working towards a scientiﬁc basis for tobacco
product regulation (WHO, 2008). As summarised by Burns et al.
(2008), TobReg concluded that chemical measurements of smoke
produced by smoking machines is probably the most effective
approach currently available for scientiﬁcally assessing differences
between products for regulatory assessment of product toxicity.
TobReg has proposed the measurement and reporting of selected
smoke toxicants and some compounds in cigarette ﬁller blends.
It has taken the further step of proposing mandated ceilings on
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detoxifying cigarette smoke (Table 1) (WHO, 2008). These pro-
posed ceilings are based on toxicant measurements determined
under the intense machine smoking regime developed by Health
Canada (HCI) when the levels are expressed as a ratio to the nico-
tine yield (Hammond et al., 2007). The developing WHO Frame-
work Convention on Tobacco Control (FCTC) represents a
mechanism whereby toxicant reporting and proposed ceiling
regulations might spread worldwide.
Several studies have reported levels of toxicants in both
cigarette smoke and the tobacco blend (Health Canada, 2004;
Gregg et al., 2004; Australian DOH, 2002). For example, compre-
hensive data on mainstream smoke constituents of contempo-
rary cigarettes, based on standardised machine-smoking
methods, have been compiled by both Borgerding et al.
(2000), who monitored 26 leading brands from the United
States by FTC/ISO parameters for 44 constituents, and Counts
et al. (2005), who analysed smoke and cigarette tobacco ﬁller
blends from 48 commercial cigarettes from international mar-
kets, smoked across 3 regimes, for tar and 44 constituents.
However, the majority of data were compiled from a single
sample of product (Borgerding et al., 2000; Counts et al.,
2005; Gregg et al., 2004; Australian DOH, 2002), providing
snapshots in time.
By contrast, fewer studies document how toxicant levels within
a given product might vary over time. Natural variation in levels
might be expected among product batches due to changes in both
the tobacco sources for the blend and process ﬂuctuations in
cigarette manufacturing steps. Design alterations in commercialTable 1
Study toxicants with regulatory relevance.
Toxicant Abbr.
Smoke
4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanone NNK
N-nitrosonornicotine NNN
Acetaldehyde
Acrolein
Acrylonitrile
4-Aminobiphenyl 4-ABP
1-Aminonaphthalene 1-AN
2-Aminonaphthalene 2-AN
Ammonia NH3
Benzene
Benzo[a]pyrene B[a]P
1,3-Butadiene
Cadmium
Carbon monoxide CO
Catechol
Crotonaldehyde
Formaldehyde
Hydrogen cyanide HCN
Hydroquinone
Isoprene
Nicotine
Nitrogen oxides NOx
Toluene
Cigarette ﬁller blend
Ammonia NH3
4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanone NNK
N-nitrosonornicotine NNN
Arsenic As
Cadmium Cd
Glycerol
Nicotine (Total)
Propylene glycol PG
Triethylene glycolcigarette products also occur from time to time, which may impact
on toxicant emission levels.
Another important source of variation is measurement uncer-
tainty, that is, analytical variation. Many studies have estimated
the variability of various smoke analyte measurements within a
single laboratory (Rickert and Wright, 2002) and across several
laboratories (Hyodo et al., 2006; Intorp et al., 2009; Teillet et al.,
2013; Purkis and Intorp, 2014). These studies, using reference
cigarettes, have concluded that smoke toxicant measurements
are generally more variable as compared with measurements of
tar, nicotine and carbon monoxide (TNCO), both within and among
laboratories, and that measurements are more variable among
laboratories than within a single laboratory. Morton and Laffoon
(2008) described both temporal cigarette and testing variation, in
their extension of a market-mapping approach to compare cigaret-
te products using the pufﬁng regime deﬁned by the Massachusetts
Department of Public Health. They noted that market maps and the
associated prediction intervals calculated from single-point-in-
time samples were likely to understate the true variability that
would be expected over time. More recently, the long-term and
short-term variability of toxicant emissions was compared for
the 9 priority smoke toxicants identiﬁed by TobReg for several
commercial cigarette products from the Japanese market
(Minagawa et al., 2012). Statistically signiﬁcant analytical
variability was also observed in the measurement of most of the
96 HPHCs on the FDAs list, using single manufactured lots of sam-
ples of 20 commercial cigarette products determined at two time-
points (Oldham et al., 2014). This paper highlights the need for
standardised analytical methods with established repeatabilityRegulatory relevance
TobReg proposal for FDA initial list
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accuracy, and inter-laboratory proﬁciency testing studies to
demonstrate laboratory capability.
An understanding of result variation is required in order to put
toxicant measurement data into context. The aim of the present
study was to provide data on the variability of smoke toxicant
emissions and cigarette ﬁller blend components for three high-vol-
ume commercial cigarette products in order to understand how
representative a sample of a commercial cigarette product taken
at a single point in time is to the general performance of a product
over time (Table 1).
2. Materials and methods
2.1. Materials
Three high-volume, internationally available, commercial
cigarette products were acquired from a single market: two British
American Tobacco (BAT) products, one at 10 mg ISO tar (product A)
and one at 4 mg ISO tar (product C), acquired directly from the BAT
factory in Bayreuth, Germany; and one high-volume commercial
product from another manufacturer at 10 mg ISO tar (product B),
purchased from a nearby German retail outlet. All three products
were king-size in length (84 cm) and circumference (24 mm),
with a single sectioned cellulose acetate ﬁlter, non-banded cigaret-
te paper and US blended style tobacco ﬁller blend, typical of the
German market. Product samples were collected monthly for 10
consecutive months from August 2010 to May 2011 inclusive.
The BAT product did not undergo any product design changes over
the course of this study; however, this aspect was unknown for the
non-BAT product.
A laboratory monitor cigarette, the University of Kentucky
(UKy) Reference Cigarette 3R4F (3R4F), was included in every
batch of analysis. The UKy reference cigarettes are manufactured
using a standard design that is speciﬁed by the University of Ken-
tucky Tobacco Research Institute. They are provided to researchers
worldwide, and are widely used, as consistent and uniform test
items for research purposes [3R4F.com]. The 3R4F reference
cigarette was manufactured under normal production tolerances
over 11 consecutive production days, producing 60 million cigar-
ettes; this amount was designed to last 10 years, with stock levels
in 2013 at 25 million (Chambers et al., 2013). This is the third pro-
duction run of this design of cigarette, subsequent production runs
of this design will be designated 4R4F, 5R4F, and so on.
2.2. Study protocol
All analyses were conducted at a single, ISO 17025 accredited
BAT laboratory. Forty-four toxicants in mainstream cigarette
smoke were determined, covering the lists of toxicants currently
required for regulatory reporting by Health Canada and ANVISA
(Health Canada, 2000; Brazil Resolution, 2007). Thirty-four compo-
nents in the cigarette tobacco blend were determined using the
analytical methods in routine use by this laboratory, again cover-
ing the lists of blend components currently required for regulatory
reporting by Health Canada and ANVISA (Health Canada, 2000;
Brazil Resolution, 2007). The three commercial products were
acquired and sent to the analytical laboratory each month over
the 10-month study period and the analysis schedule was not con-
trolled, i.e. a real-world approach to sample analysis was used.
Each sample of product was prepared for analysis according to
ISO 8243 without further selection by, for example, weight or pres-
sure drop. The three commercial product samples from a single
month were generally analysed in a single analytical batch, which
included a sample of 3R4F. In some cases, two monthly batches of
product were combined into a single analysis batch, or the threeproducts from one month were split over two analysis batches.
This resulted in between 7 and 12 analytical batches per toxicant
analysis, and correspondingly between 7 and 12 analytical samples
of 3R4F. Five replicate analyses were conducted per monthly sam-
ple of product for most toxicants because analytical experience
over the past 15 years has shown that this is more than sufﬁcient
to provide reproducible data. For TNCO, however, eight replicate
analyses were routinely conducted in accordance with the ISO
requirements for regulatory reporting (which stipulate that mea-
surements should be from an average of 40 cigarettes, equating
to 8 replicates on a linear smoking machine that smokes 5 cigar-
ettes per replicate (ISO, 2013)). Other regulators stipulate seven
replicates per analyte (FDA, 2012b; Health Canada, 2000).
2.3. Analysis methods
For mainstream smoke analyses, the products were smoked
under two smoking regimes: ISO 3308 (ISO) (ISO, 2012) and Health
Canada Intense (HCI) (Hammond et al., 2007). Because the toxi-
cants were measured by different analytical procedures, the
weight of the cigarettes used in each analysis, the puff number
and, where available, the total particulate matter (TPM) were also
recorded.
The mainstream smoke toxicants and blend components were
analysed by standard methods that have been internally validated
for repeatability and reproducibility (AOAC, 2002; ISO, 1994). Most
of these methods follow, or are based on, internationally accredited
protocols (i.e. ISO, CORESTA or ofﬁcial Health Canada methods).
The methods are multi-analyte, whereby members of a group of
toxicants (e.g. volatile organic compounds or carbonyls or aromatic
amines, etc.) are analysed simultaneously from the same cigar-
ettes. The details of the analytical methods and appropriate refer-
ences are summarised in Supplementary Tables 1 and 2, and
further details are available on request.
2.4. Data analysis
Statistical analysis was carried out using Minitab v16.0 (Mini-
tab Inc., USA) and SAS 9.3 (SAS Institute, Cary NC, USA) software.
As discussed above, toxicant emission and ﬁller blend compo-
nent levels were measured from product sampled each month
using 5 or 8 replicate analyses. The reported mean result of repli-
cate analyses from a single product sample (and the associated
SD) is the result that is usually reported for regulatory purposes
(Health Canada, 2000; FDA, 2012b). Summary statistics of these
mean monthly product sample results were used to describe toxi-
cant data per product across the study period (No. of monthly sam-
ples, mean, SD, CV). CV (%) was used to compare monthly variation
within and between products. The ratio to nicotine of each smoke
toxicant (toxicant emission/nicotine emission) was also calculated
for each monthly product sample using the mean result (of the
replicates for that monthly sample), and summary statistics deter-
mined for these ratio results (mean, SD, CV).
For data that were below the limit of detection (<LOD) or below
the limit of quantitation (<LOQ), values of ½LOD or ½(LOD + LOQ),
respectively, were used. If the majority of the replicates were
<LOQ, then SD and CV were not reported.
The empirical rule that 2 SD gives an approximation of the
95% conﬁdence intervals around the mean for a normal distribu-
tion was used to estimate the within-laboratory ‘tolerance’ around
a single measured value. All replicate results for each product were
visually screened to check for normality (histogram of all repli-
cates, plus comparison of 95% conﬁdence intervals of mean and
median results). All results were approximately normal, with a
few exceptions where results were near or below LOQ (nitrite,
myosmine, triacetin in the ﬁller blend plus some of the metals in
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ly normally distributed to apply this empirical rule.
3. Results
3.1. Monthly variation in ﬁller blend components
Over the 10-month study period, the levels of 34 blend compo-
nents were measured for three commercial products and the moni-
tor cigarette Kentucky Reference 3R4F. The mean ± SD levels of
these blend components were used to determine the monthly var-
iation (Table 2). Levels of nicotine, nitrate, ammonia and TSNAs in
the cigarette ﬁller blends were generally consistent with previous-
ly reported levels (Counts et al., 2005).
Variation in the levels of blend components ranged from under
2% CV for total alkaloids and total sugar levels in 3R4F, to over 20%
for B[a]P, caffeic acid and cadmium in the three commercial prod-
ucts. Overall, however, variation in blend component levels was
generally low (<10% CV).
The variation in toxicant levels in 3R4F (which was produced at
effectively a single point in time) was compared with that in the
commercial products (which were obtained at monthly intervals)
to give an indication of month-to-month manufacturing batch
variability among the commercial products. Thus, the ratio of the
average CV for the three commercial products to the CV for 3R4F
was determined for each blend component (Table 2). Across all
blend measurements, the CV ratio averaged 1.7, ranging from less
than 1 for nicotine and glycerol, to greater than 2 for total and
reducing sugars, NNN, chlorogenic acid and cadmium (Table 2).
So on average, variation was 70% higher for a repeatedly made pro-
duct than for a single batch product, and more than twice as high
for total and reducing sugars, NNN, chlorogenic acid and cadmium.
Estimates of the within-laboratory ‘tolerance’ around a single
measured value were made for each blend component using 2SD
and the associated 2CV to give percentage values. For the commer-
cial products, 2CV values ranged from <10%, for total alkaloids,
chloride, total nitrogen, protein nitrogen and nicotine, to 50%
for B[a]P, caffeic acid and cadmium. For 3R4F, by contrast, 2CV val-
ues ranged from <10% for total alkaloids, total and reducing sugar,
chloride, total and protein nitrogen, nitrate, chlorogenic acid and
rutin, to a maximum of 34.2% for B[a]P.
3.2. Monthly variation in smoke toxicant emission levels
Over the 10-month study period, the emission levels of 44
smoke toxicants were measured for three commercial products
and the monitor cigarette Kentucky Reference 3R4F under both
the ISO and HCI regimes. The mean ± SD levels of toxicant emis-
sions from these cigarette samples were generally consistent with
previously reported levels (Gregg et al., 2004; Counts et al., 2005),
and were used to determine the monthly variation (Table 3).
Variation in toxicant emissions ranged from less than 5% CV for
TNCO under both ISO and HCI regimes and acetaldehyde under the
HCI regime, to >20% for 1,3-butadiene under the HCI regime for all
four products, resorcinol under the ISO regime and arsenic under
the HCI regime for the commercial products.
Overall, however, variation was generally low with CV values
often less than 10%. Under both regimes, TSNAs, phenols, semi-
volatiles and HCN analyses tended to give more variable results
for each product (CV 10–20%) as well as a few individual analytes
including: water determination under ISO; formaldehyde and cro-
tonaldehyde emissions under either regime; several of the aromat-
ic amines under either regime and Cadmium under either regime
(Table 3). As mentioned above, 1,3-butadiene under HCI, resorcinol
under ISO and arsenic under HCI produced results with the highest
variation (CV > 20%).As above, the CV ratio (average CV for the three commercial
products/CV for 3R4F) was calculated to evaluate the month-to-
month effect of manufacturing batch for each toxicant (Table 3).
The average CV ratio across all smoke toxicants was 1.7 under
ISO and 1.5 under HCI, i.e. 70% and 50% more variable for a repeat-
edly made product. The CV ratio ranged from 0.7 for 1,3-butadiene
under HCI and toluene under ISO, to more than 2.0 for: nicotine
under ISO (driven by a high CV of 14% for product C); NNK, NNN
and NAT under ISO; 2-AN and 4-ABP under HCI; o-cresol, m-cresol
and hydroquinone under ISO; phenol, o-cresol and p-cresol under
HCI; HCN under ISO; arsenic under HCI, and cadmium under ISO.
Butyraldehyde under HCI had a notably high CV ratio (5.8) driven
by an atypically low CV for 3R4F (2.6%).
Estimates of awithin-laboratory ‘tolerance’ around a singlemea-
sured value were made for each smoke toxicant using 2SD and the
associated 2CV to give percentage values. For the commercial prod-
ucts, 2CV values ranged from <10% for TNCO analyses under both
regimes (although the lower, 4 mg ISO tar product C was more vari-
able under ISO at 13–14%); to greater than 40% for: 1,3-butadiene
under HCI; resorcinol under ISO (commercial products only); NNK
under both regimes for product A (products B and C, 20–23% and
27–29%, respectively); quinoline under ISO for product C (products
A and B, 32% and 36% respectively); and arsenic under HCI for prod-
ucts A and B (product C under HCI and all commercial products
under ISO were below LOQ). For 3R4F, by contrast, 2CV values
ranged from <10%, for TNCO analyses under both regimes, to a
maximum of 57% for 1,3-butadiene under HCI (Table 3).
The variation in toxicant emissions generated under the two
regimes was contrasted by calculating the ratio of CV under HCI
to CV under ISO (Table 3). These ratios averaged 0.9 over all the
smoke toxicants with 72% of results less than 1.0, indicating that
results obtained under ISO smoking conditions were generally
slightly more variable than results obtained under HCI smoking
conditions.3.3. Monthly variation in toxicant emission levels as a ratio to nicotine
In keeping with TobReg recommendations to establish levels for
selected toxicant emissions per mg of nicotine under HCI condi-
tions (WHO, 2008), the variation in toxicant emissions was calcu-
lated as a ratio to nicotine for 23 toxicants of current regulatory
interest (Table 4), including 9 toxicants proposed for mandated
lowering by TobReg, 9 proposed for measurement and reporting
by TobReg, and 5 other toxicants on the FDA’s initial list that are
not on the TobReg list.
When expressed as a ratio to nicotine, the CVs of toxicant emis-
sion measurements (Table 4) were similar to the CVs for absolute
toxicant emission measurements under HCI conditions (Table 3)
with increased variation of the order of 2.9 to 3.4 percentage
points in analytes for each product (Table 4). The average differ-
ence between the ratio to nicotine CV and the absolute emission
level CV was 1.4 percentage points.
Regarding the 9 toxicants proposed for mandated lowering by
TobReg, the CV of the ratio to nicotine data was typically 1–2 per-
centage points higher than the CV determined for absolute mea-
surements. By contrast, the CV as a ratio to nicotine for aromatic
amines, phenol and some cadmium emission data tended to be
lower than that for the corresponding absolute measurements.4. Discussion
The present single-centre analysis has measured the monthly
variation in key toxicants in both the tobacco blend and smoke
of a monitor cigarette (3R4F) and three commercial products
sampled over 10 months. In general, the month-to-month
Table 2
Ten-month variation in levels of cigarette ﬁller components.
Analysis Analyte Unitsc Product Cigarette ﬁller blend components
Sample No. Mean SD CV (%) 2SD 2CV (%) CV ratioa
Blend chemistry Total alkaloids %dwb 3R4F 12 1.84 0.04 1.9 0.07 3.8 2.0
A 10 1.86 0.08 4.6 0.17 9.1
B 10 1.75 0.06 3.6 0.13 7.3
C 10 1.93 0.06 3.1 0.12 6.2
Total sugar %dwb 3R4F 12 11.8 0.2 1.9 0.4 3.7 3.1
A 10 10.7 0.6 5.9 1.3 11.8
B 10 13.7 0.6 4.7 1.3 9.4
C 10 10.3 0.7 7.1 1.5 14.1
Reducing sugars %dwb 3R4F 12 10.2 0.3 2.6 0.5 5.2 2.6
A 10 7.9 0.6 7.7 1.2 15.4
B 10 8.6 0.5 5.3 0.9 10.6
C 10 7.6 0.6 7.7 1.2 15.4
B[a]Pb ng/g dwb 3R4F 11 10.0 1.7 17.1 3.43 34.2 1.5
A 10 22.2 5.8 26.1 11.55 52.1
B 10 19.9 5.3 26.5 10.56 53.1
C 10 36.7 8.3 22.5 16.53 45.0
Chloride %dwb 3R4F 12 0.89 0.03 3.3 0.06 6.6 1.4
A 10 0.84 0.06 6.7 0.11 13.3
B 10 0.75 0.03 3.6 0.05 7.3
C 10 0.85 0.03 3.3 0.06 6.7
Nitrogenous compounds Total nitrogen %dwb 3R4F 12 2.51 0.05 2.1 0.10 4.2 1.7
A 10 2.85 0.11 4.0 0.23 7.9
B 10 2.62 0.09 3.2 0.17 6.5
C 10 2.89 0.09 3.2 0.18 6.3
Protein nitrogen %dwb 3R4F 11 1.21 0.03 2.7 0.07 5.5 1.7
A 10 1.40 0.06 4.4 0.12 8.9
B 10 1.29 0.06 4.9 0.13 9.9
C 10 1.38 0.06 4.2 0.12 8.4
Ammoniumb lg/g dwb 3R4F 12 1055 56 5.3 112 10.7 1.5
A 10 1354 136 10.1 273 20.2
B 10 1239 62 5.0 125 10.1
C 10 1483 124 8.4 248 16.7
Nitrate ion %dwb 3R4F 12 1.06 0.03 3.2 0.07 6.5 1.9
A 10 0.73 0.06 8.7 0.13 17.5
B 10 0.74 0.03 3.9 0.06 7.7
C 10 0.74 0.05 6.1 0.09 12.3
Nitrite ion lg/g dwb 3R4F 12 <1.00
A 10 <1.00
B 10 <1.00
C 10 <1.00
Individual alkaloids Nicotineb %dwb 3R4F 12 2.25 0.12 5.1 0.23 10.3 0.8
A 10 2.23 0.08 3.4 0.15 6.9
B 10 2.13 0.09 4.1 0.17 8.1
C 10 2.31 0.10 4.2 0.19 8.3
Nornicotine %dwb 3R4F 12 0.091 0.010 10.6 0.019 21.2 1.2
A 10 0.155 0.023 14.5 0.045 29.1
B 10 0.109 0.013 12.1 0.026 24.1
C 10 0.157 0.020 12.6 0.040 25.3
Anabasine %dwb 3R4F 12 0.010
A 10 0.017 0.003 16.6 0.006 33.1
B 10 0.016 0.002 13.8 0.004 27.6
C 10 0.017 0.003 15.7 0.005 31.5
Anatabine %dwb 3R4F 12 0.092 0.006 6.6 0.012 13.2 1.1
A 10 0.109 0.008 7.7 0.017 15.3
B 10 0.101 0.006 5.6 0.011 11.1
C 10 0.114 0.010 9.1 0.021 18.3
Myosmine %dwb 3R4F 12 <0.010
A 10 <0.010
B 10 <0.010
C 10 <0.010
Polyphenols Chlorogenic acid mg/g dwb 3R4F 12 3.36 0.07 2.2 0.15 4.4 3.3
A 10 3.33 0.21 6.3 0.42 12.6
B 10 3.98 0.24 6.1 0.49 12.2
C 10 3.51 0.32 9.2 0.65 18.4
Caffeic acid mg/g dwb 3R4F 12 0.10 0.01 13.9 0.03 27.9 2.0
A 10 0.16 0.04 26.9 0.09 53.8
B 10 0.12 0.04 35.1 0.08 70.1
C 10 0.17 0.04 23.4 0.08 46.7
Rutin mg/g dwb 3R4F 12 2.29 0.07 3.1 0.14 6.1 1.9
A 10 3.50 0.20 5.6 0.40 11.3
B 10 3.42 0.17 4.9 0.33 9.8
(continued on next page)
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Table 2 (continued)
Analysis Analyte Unitsc Product Cigarette ﬁller blend components
Sample No. Mean SD CV (%) 2SD 2CV (%) CV ratioa
C 10 3.55 0.24 6.9 0.49 13.8
Scopoletin mg/g dwb 3R4F 12 0.28 0.04 14.8 0.08 29.6 1.2
A 10 0.31 0.06 19.6 0.12 39.1
B 10 0.23 0.03 11.7 0.05 23.5
C 10 0.33 0.07 20.2 0.13 40.3
Tobacco speciﬁc nitrosamines NNNb lg/g dwb 3R4F 10 2.40 0.15 6.4 0.31 12.9 2.2
A 10 2.08 0.38 18.4 0.76 36.7
B 10 1.04 0.09 8.5 0.18 16.9
C 10 1.77 0.26 14.8 0.53 29.6
NAB lg/g dwb 3R4F 10 0.13 0.02 15.2 0.04 30.4 1.0
A 10 0.11 0.01 14.0 0.03 28.1
B 10 0.09 0.02 23.1 0.04 46.3
C 10 0.10 0.01 7.7 0.02 15.4
NAT lg/g dwb 3R4F 10 2.00 0.12 6.1 0.24 12.2 1.7
A 10 1.14 0.17 15.2 0.34 30.3
B 10 0.98 0.08 7.7 0.15 15.4
C 10 0.96 0.07 7.6 0.15 15.1
NNKb lg/g dwb 3R4F 10 0.71 0.06 7.8 0.11 15.7 1.5
A 10 0.30 0.04 12.9 0.08 25.8
B 10 0.34 0.04 13.3 0.09 26.6
C 10 0.28 0.03 10.0 0.06 20.0
Total TSNA lg/g dwb 3R4F 10 5.24 0.34 6.4 0.67 12.8 1.8
A 10 3.63 0.58 15.9 1.15 31.7
B 10 2.45 0.19 7.8 0.38 15.5
C 10 3.11 0.31 10.0 0.62 20.1
Metals Lead lg/g dwb 3R4F 12 0.425 0.033 7.8 0.066 15.6 1.8
A 10 0.522 0.088 16.8 0.175 33.6
B 10 0.472 0.064 13.6 0.128 27.1
C 10 0.620 0.076 12.3 0.152 24.5
Chromium lg/g dwb 3R4F 12 0.831 0.092 11.1 0.185 22.3 1.4
A 10 1.306 0.147 11.2 0.293 22.5
B 10 1.211 0.259 21.4 0.518 42.8
C 10 0.960 0.139 14.5 0.278 29.0
Nickel lg/g dwb 3R4F 12 1.477 0.095 6.4 0.189 12.8 1.5
A 10 2.046 0.193 9.5 0.387 18.9
B 10 1.959 0.244 12.5 0.488 24.9
C 10 1.579 0.113 7.2 0.227 14.4
Cadmiumb lg/g dwb 3R4F 12 0.988 0.098 9.9 0.196 19.9 2.3
A 10 0.789 0.174 22.0 0.347 44.0
B 10 0.712 0.158 22.2 0.317 44.5
C 10 0.971 0.242 24.9 0.483 49.8
Mercury lg/g dwb 3R4F 12 <0.031
A 10 <0.031
B 10 <0.031
C 10 <0.031
Arsenicb lg/g dwb 3R4F 12 0.251 0.023 9.2 0.046 18.3 1.3
A 10 0.211 0.029 13.6 0.057 27.2
B 10 0.207 0.021 10.3 0.042 20.5
C 10 0.181 0.024 13.2 0.048 26.4
Selenium lg/g dwb 3R4F 12 <0.130
A 10 <0.130
B 10 <0.130
C 10 <0.130
Humectants Glycerolb mg/g dwb 3R4F 12 23.44 2.04 8.7 4.08 17.4 0.7
A 10 21.12 1.56 7.4 3.12 14.8
B 10 17.04 0.72 4.2 1.44 8.5
C 10 19.27 1.49 7.7 2.98 15.5
Propylene glycolb mg/g dwb 3R4F 12 <0.75
A 10 12.63 0.80 6.3 1.59 12.6
B 10 12.06 0.42 3.5 0.84 7.0
C 10 9.62 0.50 5.2 1.00 10.4
Triethylene glycolb mg/g dwb 3R4F 12 <0.75
A 10 <0.75
B 10 <0.75
C 10 <0.75
Triacetin mg/g dwb 3R4F 12 <0.75
A 10 0.87 0.01 0.7 0.01 1.3
B 10 <0.75
C 10 <0.75
a CV ratio = mean CV commercial product/CV 3R4F.
b Blend ﬁller components of regulatory relevance (Table 1).
c dwb: dry weight basis.
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Table 3
Ten-month variation in emission levels of mainstream smoke toxicants from four products smoked under ISO and HCI conditions.
Analysis Analyte Units Product ISO smoking regime HCI smoking regime HCI CV/ISO
CV
No.
samples
Mean SD CV
(%)
2 SD 2 CV
(%)
CV
ratioa
No.
samples
Mean SD CV
(%)
2 SD 2 CV
(%)
CV
ratioa
Tar, nicotine and CO Cigarette weight mg/cig 3R4F 10 1029 3 0.3 6 0.6 2.3 7 1027 5 0.4 9 0.9 1.6
A 10 912 8 0.9 17 1.8 10 908 6 0.7 13 1.4
B 10 886 6 0.7 13 1.4 10 884 6 0.7 13 1.5
C 10 835 4 0.5 8 1.0 10 832 6 0.8 13 1.6
Puff No. 3R4F 10 8.2 0.1 1.5 0.2 2.9 1.6 7 10.4 0.2 1.7 0.3 3.4 1.3
A 10 8.3 0.1 1.2 0.2 2.3 10 10.7 0.2 1.5 0.3 3.0
B 10 7.8 0.2 2.7 0.4 5.4 10 10.0 0.3 3.4 0.7 6.8
C 10 7.5 0.2 2.9 0.4 5.8 10 8.7 0.1 1.7 0.3 3.4
TPM mg/cig 3R4F 10 9.5 0.4 3.7 0.7 7.4 1.3 7 44.1 1.4 3.2 2.8 6.4 0.9
A 10 13.2 0.5 4.1 1.1 8.3 10 51.8 0.9 1.7 1.8 3.4
B 10 11.9 0.4 3.5 0.8 7.0 10 48.2 1.8 3.7 3.6 7.5
C 10 4.9 0.3 6.4 0.6 12.8 10 35.3 1.2 3.3 2.3 6.6
Tar mg/cig 3R4F 10 7.9 0.3 3.9 0.6 7.7 1.2 7 26.3 0.7 2.6 1.4 5.3 0.9
A 10 10.8 0.4 3.9 0.8 7.9 10 31.4 0.5 1.7 1.1 3.4
B 10 9.7 0.3 2.6 0.5 5.2 10 29.0 0.9 3.2 1.8 6.3
C 10 4.1 0.3 6.8 0.6 13.6 10 20.8 0.5 2.6 1.1 5.2
Nicotineb mg/cig 3R4F 10 0.73 0.02 2.3 0.03 4.6 2.2 7 1.97 0.04 2.3 0.09 4.6 1.6 1.0
A 10 0.95 0.04 4.6 0.09 9.2 10 2.33 0.08 3.2 0.15 6.4 0.7
B 10 0.85 0.03 3.0 0.05 6.1 10 2.13 0.08 3.7 0.16 7.5 1.2
C 10 0.43 0.03 7.2 0.06 14.4 10 1.56 0.07 4.2 0.13 8.5 0.6
Water mg/cig 3R4F 10 0.9 0.1 11.7 0.2 23.3 1.0 7 15.9 0.7 4.7 1.5 9.3 1.0 0.4
A 10 1.5 0.2 15.9 0.5 31.7 10 18.0 0.6 3.5 1.3 7.1 0.2
B 10 1.3 0.2 11.7 0.3 23.5 10 17.1 1.0 5.7 1.9 11.4 0.5
C 10 0.3 0.0 6.6 0.0 13.2 10 12.9 0.7 5.3 1.4 10.7 0.8
COb mg/cig 3R4F 10 10.7 0.4 4.0 0.9 8.1 1.2 7 31.2 1.0 3.1 1.9 6.2 0.9 0.8
A 10 9.6 0.4 4.1 0.8 8.2 10 26.8 0.7 2.7 1.5 5.4 0.7
B 10 8.9 0.3 3.7 0.7 7.4 10 26.1 0.8 3.1 1.6 6.1 0.8
C 10 5.0 0.3 6.6 0.7 13.1 10 23.0 0.6 2.8 1.3 5.6 0.4
TSNA Cigarette weight mg/cig 3R4F 8 1037 3 0.3 6 0.6 3.1 9 1079 9 0.9 18 1.7 1.2
A 10 923 8 0.9 16 1.8 10 961 10 1.0 20 2.0
B 10 898 7 0.7 13 1.5 10 936 9 1.0 18 2.0
C 10 847 9 1.1 18 2.2 10 886 11 1.2 21 2.4
Puff No. 3R4F 8 7.9 0.2 2.1 0.3 4.1 1.4 9 10.6 0.2 1.4 0.3 2.9 1.6
A 10 7.9 0.2 2.9 0.5 5.8 10 10.9 0.3 2.8 0.6 5.5
B 10 7.5 0.2 3.1 0.5 6.1 10 10.2 0.2 2.0 0.4 4.1
C 10 7.2 0.2 2.6 0.4 5.3 10 8.9 0.2 2.2 0.4 4.4
TPM mg/cig 3R4F 8 9.9 0.4 4.3 0.9 8.7 1.5 9 44.1 1.3 2.9 2.5 5.8 1.0
A 10 13.4 0.9 6.8 1.8 13.6 10 50.9 1.6 3.1 3.2 6.2
B 10 12.2 0.7 5.5 1.3 11.1 10 49.8 0.9 1.9 1.8 3.7
C 10 5.6 0.4 7.8 0.9 15.6 10 36.6 1.5 4.0 2.9 8.0
NNKb ng/cig 3R4F 8 103.6 6.8 6.6 13.6 13.1 2.4 9 309.6 27.6 8.9 55.2 17.8 1.7 1.4
A 10 50.5 11.1 21.9 22.1 43.8 10 131.0 27.2 20.8 54.4 41.5 0.9
B 10 56.5 8.1 14.3 16.2 28.7 10 151.3 20.3 13.4 40.6 26.8 0.9
C 10 21.4 2.4 11.3 4.8 22.6 10 78.1 7.8 10.0 15.5 19.9 0.9
NNNb ng/cig 3R4F 8 113.5 5.3 4.6 10.5 9.3 3.2 9 311.6 20.6 6.6 41.1 13.2 2.0 1.4
A 10 138.7 26.7 19.2 53.3 38.5 10 329.1 55.8 17.0 111.6 33.9 0.9
B 10 67.2 7.6 11.3 15.2 22.7 10 163.5 13.6 8.3 27.3 16.7 0.7
C 10 60.4 8.1 13.4 16.2 26.8 10 215.1 30.8 14.3 61.6 28.6 1.1
NAB ng/cig 3R4F 8 14.1 0.8 5.4 1.5 10.8 1.9 9 37.0 3.0 8.1 6.0 16.2 1.2 1.5
A 10 12.7 1.4 10.8 2.7 21.7 10 29.8 1.7 5.8 3.5 11.6 0.5
B 10 9.9 0.8 8.1 1.6 16.2 10 23.1 2.4 10.5 4.9 21.0 1.3
C 10 6.0 0.7 11.6 1.4 23.1 10 20.5 2.8 13.9 5.7 27.7 1.2
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Table 3 (continued)
Analysis Analyte Units Product ISO smoking regime HCI smoking regime HCI CV/ISO
CV
No.
samples
Mean SD CV
(%)
2 SD 2 CV
(%)
CV
ratioa
No.
samples
Mean SD CV
(%)
2 SD 2 CV
(%)
CV
ratioa
NAT ng/cig 3R4F 8 125.4 5.4 4.3 10.8 8.6 2.8 9 323.0 22.9 7.1 45.9 14.2 1.1 1.7
A 10 99.9 13.5 13.5 27.1 27.1 10 228.8 22.3 9.7 44.6 19.5 0.7
B 10 85.0 9.1 10.8 18.3 21.5 10 198.2 16.2 8.2 32.5 16.4 0.8
C 10 47.3 5.5 11.6 11.0 23.2 10 156.8 9.0 5.8 18.1 11.5 0.5
Carbonyls Cigarette weight mg/cig 3R4F 9 1041 8 0.8 16 1.6 1.1 10 1081 11 1.0 22 2.0 1.4
A 10 924 8 0.9 17 1.8 10 963 20 2.0 39 4.1
B 10 899 11 1.2 21 2.3 10 943 12 1.3 24 2.5
C 10 842 4 0.4 8 0.9 10 886 8 0.9 16 1.8
Puff No. 3R4F 9 8.7 0.1 1.3 0.2 2.6 2.0 10 10.6 0.3 3.0 0.6 5.9 1.0
A 10 8.6 0.2 2.5 0.4 4.9 10 11.0 0.3 2.5 0.5 5.0
B 10 8.2 0.2 2.5 0.4 5.1 10 10.2 0.2 2.4 0.5 4.8
C 10 7.7 0.2 2.7 0.4 5.5 10 9.0 0.3 3.9 0.7 7.7
Formaldehydeb lg/cig 3R4F 9 25.0 1.6 6.3 3.2 12.7 1.7 10 72.2 5.8 8.0 11.5 16.0 1.5 1.3
A 10 25.0 2.5 10.2 5.1 20.3 10 65.6 6.4 9.7 12.8 19.5 1.0
B 10 34.3 4.3 12.4 8.5 24.8 10 92.7 11.0 11.9 22.0 23.8 1.0
C 10 9.0 0.9 10.0 1.8 20.0 10 46.8 7.2 15.4 14.4 30.8 1.5
Acetaldehydeb lg/cig 3R4F 9 469 20 4.3 40 8.5 1.6 10 1235 39 3.1 77 6.3 1.6 0.7
A 10 428 32 7.4 64 14.9 10 1090 49 4.5 97 8.9 0.6
B 10 416 27 6.5 54 12.9 10 1103 39 3.5 78 7.1 0.5
C 10 243 15 6.4 31 12.8 10 973 71 7.3 143 14.7 1.2
Acetone lg/cig 3R4F 9 199 7 3.7 15 7.4 2.0 10 576 33 5.8 67 11.6 1.0 1.6
A 10 186 13 7.1 26 14.1 10 514 29 5.6 58 11.3 0.8
B 10 177 12 7.0 25 14.0 10 508 20 4.0 40 8.0 0.6
C 10 103 8 7.6 16 15.2 10 447 38 8.6 77 17.2 1.1
Acroleinb lg/cig 3R4F 9 52.2 3.2 6.1 6.3 12.1 1.2 10 124.9 8.5 6.8 17.0 13.6 1.0 1.1
A 10 48.5 3.8 7.9 7.7 15.9 10 113.7 8.1 7.1 16.2 14.3 0.9
B 10 48.5 4.0 8.2 8.0 16.5 10 120.7 6.1 5.0 12.2 10.1 0.6
C 10 24.9 1.4 5.8 2.9 11.6 10 100.0 8.5 8.5 16.9 16.9 1.5
Propionaldehyde lg/cig 3R4F 9 45.0 2.5 5.6 5.1 11.3 1.3 10 129.7 6.0 4.6 11.9 9.2 1.4 0.8
A 10 44.9 3.5 7.8 7.0 15.6 10 127.2 8.3 6.6 16.7 13.1 0.8
B 10 43.7 3.3 7.6 6.6 15.1 10 129.8 7.0 5.4 14.0 10.8 0.7
C 10 24.2 1.5 6.3 3.0 12.5 10 105.2 8.3 7.9 16.6 15.8 1.3
MEK lg/cig 3R4F 9 52.4 3.5 6.7 7.1 13.5 1.2 10 158.7 8.0 5.0 16.0 10.1 1.2 0.7
A 10 48.3 3.3 6.9 6.6 13.7 10 140.2 8.5 6.1 17.0 12.2 0.9
B 10 47.2 4.0 8.6 8.1 17.1 10 138.7 5.2 3.8 10.4 7.5 0.4
C 10 26.0 2.3 8.8 4.6 17.6 10 119.6 10.7 9.0 21.5 17.9 1.0
Crotonaldehydeb lg/cig 3R4F 9 10.7 0.9 8.1 1.7 16.2 1.5 10 46.4 3.6 7.8 7.3 15.6 1.1 1.0
A 10 12.1 1.5 12.0 2.9 24.0 10 46.4 3.6 7.7 7.1 15.4 0.6
B 10 12.0 1.4 11.4 2.7 22.9 10 47.1 3.5 7.5 7.0 14.9 0.7
C 10 4.8 0.7 13.9 1.3 27.8 10 37.9 4.3 11.2 8.5 22.5 0.8
Butyraldehyde lg/cig 3R4F 9 33.6 1.9 5.7 3.8 11.3 1.6 10 86.8 1.1 1.3 2.2 2.6 5.8 0.2
A 10 37.6 3.7 9.8 7.4 19.6 10 106.2 7.2 6.7 14.3 13.5 0.7
B 10 34.2 3.1 9.2 6.3 18.4 10 99.5 7.7 7.8 15.5 15.6 0.8
C 10 20.5 1.6 8.0 3.3 15.9 10 90.4 7.2 8.0 14.5 16.0 1.0
Miscellaneous organic
compounds
Cigarette weight mg/cig 3R4F 9 1038 4 0.4 7 0.7 2.0 8 1053 16 1.5 32 3.0 0.7
A 10 919 8 0.9 17 1.8 10 959 10 1.0 19 2.0
B 10 893 6 0.7 13 1.4 10 934 7 0.8 15 1.6
C 10 839 4 0.5 9 1.1 10 887 11 1.2 21 2.4
Puff No. 3R4F 9 8.4 0.1 1.1 0.2 2.3 1.7 8 10.5 0.5 4.5 1.0 9.1 0.7
A 10 8.3 0.2 2.7 0.5 5.5 10 10.8 0.3 2.9 0.6 5.7
B 10 8.0 0.1 1.6 0.3 3.2 10 10.0 0.3 3.2 0.6 6.3
C 10 7.6 0.1 1.4 0.2 2.8 10 8.9 0.3 3.9 0.7 7.8
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TPM mg/cig 3R4F 9 10.1 0.5 4.6 0.9 9.2 1.0 8 43.6 1.2 2.8 2.4 5.6 1.6
A 10 13.7 0.5 3.9 1.1 7.8 10 51.8 2.1 4.1 4.2 8.2
B 10 12.4 0.7 5.7 1.4 11.3 10 48.3 1.9 3.9 3.8 7.9
C 10 5.4 0.2 4.0 0.4 7.9 10 34.9 1.9 5.4 3.8 10.8
1,3-Butadieneb lg/cig 3R4F 9 30.5 2.6 8.7 5.3 17.3 0.8 8 90.5 25.8 28.6 51.7 57.1 0.7 3.3
A 10 35.1 2.1 6.1 4.3 12.2 10 90.3 19.0 21.0 38.0 42.0 3.5
B 10 30.6 2.8 9.3 5.7 18.5 10 80.9 17.3 21.4 34.6 42.8 2.3
C 10 20.2 1.3 6.4 2.6 12.8 10 80.9 16.4 20.3 32.8 40.6 3.2
Isopreneb lg/cig 3R4F 9 347 22 6.3 43 12.5 1.1 8 1042 76 7.3 151 14.5 0.9 1.2
A 10 373 28 7.5 56 15.0 10 1013 70 6.9 140 13.8 0.9
B 10 329 29 8.9 59 17.9 10 922 52 5.6 104 11.2 0.6
C 10 207 9 4.2 17 8.3 10 870 59 6.8 118 13.6 1.6
Acrylonitrileb lg/cig 3R4F 9 10.7 0.5 4.7 1.0 9.3 2.0 8 33.7 1.5 4.4 3.0 8.9 1.7 0.9
A 10 12.6 0.8 6.5 1.6 13.0 10 37.4 2.3 6.1 4.6 12.2 0.9
B 10 11.0 1.0 8.7 1.9 17.4 10 32.4 2.2 6.8 4.4 13.6 0.8
C 10 6.1 0.8 12.9 1.6 25.7 10 32.8 3.2 9.7 6.4 19.4 0.8
Benzeneb lg/cig 3R4F 9 43.4 1.6 3.7 3.2 7.3 1.8 8 99.2 5.6 5.6 11.2 11.3 1.1 1.5
A 10 45.5 2.2 4.8 4.4 9.6 10 98.5 5.3 5.3 10.5 10.7 1.1
B 10 40.1 2.8 6.9 5.5 13.7 10 86.5 4.5 5.2 9.0 10.5 0.8
C 10 27.9 2.2 7.9 4.4 15.8 10 83.5 6.5 7.7 12.9 15.5 1.0
Tolueneb lg/cig 3R4F 9 64.5 6.1 9.4 12.1 18.8 0.7 8 164.0 8.4 5.1 16.9 10.3 1.0 0.5
A 10 70.1 5.9 8.5 11.9 16.9 10 166.1 9.5 5.7 18.9 11.4 0.7
B 10 61.1 3.1 5.1 6.2 10.1 10 142.2 4.7 3.3 9.4 6.6 0.6
C 10 38.0 1.9 5.0 3.8 9.9 10 129.5 8.0 6.2 16.1 12.4 1.2
Aromatic amines Cigarette weight mg/cig 3R4F 9 1037 4 0.4 8 0.8 2.3 7 1075 14 1.3 28 2.6 0.9
A 10 921 8 0.9 17 1.8 10 960 12 1.2 23 2.4
B 10 896 7 0.7 13 1.5 10 936 9 0.9 18 1.9
C 10 839 9 1.0 18 2.1 10 884 11 1.2 21 2.4
Puff No. 3R4F 9 7.9 0.1 0.8 0.1 1.5 2.7 7 10.7 0.2 1.6 0.3 3.1 1.5
A 10 7.9 0.1 1.5 0.2 3.1 10 10.8 0.3 2.6 0.6 5.2
B 10 7.5 0.2 2.2 0.3 4.5 10 10.2 0.2 1.6 0.3 3.2
C 10 7.1 0.2 2.4 0.3 4.8 10 8.8 0.2 2.7 0.5 5.3
TPM mg/cig 3R4F 9 10.3 0.5 4.7 1.0 9.5 1.0 7 45.9 2.3 5.1 4.6 10.1 0.9
A 10 13.5 0.7 4.9 1.3 9.7 10 52.4 2.0 3.9 4.1 7.7
B 10 12.2 0.5 4.1 1.0 8.2 10 50.4 2.2 4.3 4.3 8.6
C 10 5.6 0.3 5.6 0.6 11.2 10 36.6 2.1 5.8 4.3 11.6
1-ANb ng/cig 3R4F 9 13.6 1.3 9.7 2.6 19.3 0.9 7 22.9 1.5 6.3 2.9 12.7 1.4 0.7
A 10 17.5 1.7 9.7 3.4 19.5 10 29.5 2.3 7.8 4.6 15.6 0.8
B 10 15.5 1.2 7.8 2.4 15.5 10 26.5 3.0 11.3 6.0 22.7 1.5
C 10 8.3 0.8 10.0 1.6 19.9 10 18.8 1.5 7.9 3.0 15.9 0.8
2-ANb ng/cig 3R4F 9 7.7 0.5 6.3 1.0 12.5 1.1 7 13.4 0.5 3.7 1.0 7.3 2.1 0.6
A 10 9.9 0.9 8.6 1.7 17.2 10 16.6 1.1 6.8 2.3 13.6 0.8
B 10 8.5 0.4 4.8 0.8 9.7 10 14.7 1.5 10.1 3.0 20.3 2.1
C 10 4.7 0.4 7.9 0.8 15.8 10 10.9 0.6 5.8 1.3 11.5 0.7
3-ABP ng/cig 3R4F 9 1.93 0.18 9.5 0.37 19.1 1.3 7 4.51 0.47 10.3 0.93 20.7 1.3 1.1
A 10 2.56 0.36 14.0 0.72 28.0 10 5.62 0.69 12.3 1.39 24.7 0.9
B 10 2.14 0.22 10.4 0.45 20.9 10 4.82 0.73 15.1 1.46 30.2 1.4
C 10 1.27 0.17 13.2 0.34 26.5 10 3.83 0.48 12.6 0.96 25.1 1.0
4-ABPb ng/cig 3R4F 9 1.15 0.07 6.4 0.15 12.8 0.9 7 2.66 0.11 4.3 0.23 8.6 2.2 0.7
A 10 1.61 0.11 6.5 0.21 13.1 10 3.64 0.30 8.2 0.60 16.4 1.3
B 10 1.31 0.06 4.4 0.11 8.7 10 3.04 0.33 10.9 0.66 21.8 2.5
C 10 0.83 0.05 6.1 0.10 12.2 10 2.60 0.23 8.9 0.46 17.7 1.4
Phenols Cigarette weight mg/cig 3R4F 9 1036 6 0.6 12 1.1 1.8 8 1042 9 0.9 18 1.7 1.8
A 10 916 11 1.2 22 2.4 10 962 11 1.2 23 2.4
B 10 895 7 0.7 13 1.5 10 936 16 1.7 32 3.4
C 10 845 9 1.1 18 2.1 10 883 15 1.7 30 3.4
Puff No. 3R4F 9 8.4 0.1 1.7 0.3 3.5 1.7 8 11.0 0.5 4.7 1.0 9.4 0.7
A 10 8.3 0.2 2.5 0.4 5.0 10 10.8 0.3 2.8 0.6 5.7
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Table 3 (continued)
Analysis Analyte Units Product ISO smoking regime HCI smoking regime HCI CV/ISO
CV
No.
samples
Mean SD CV
(%)
2 SD 2 CV
(%)
CV
ratioa
No.
samples
Mean SD CV
(%)
2 SD 2 CV
(%)
CV
ratioa
B 10 8.0 0.2 3.1 0.5 6.2 10 10.3 0.5 4.7 1.0 9.3
C 10 7.7 0.3 3.5 0.5 7.0 10 9.0 0.3 3.1 0.6 6.1
TPM mg/cig 3R4F 9 9.5 0.8 7.9 1.5 15.8 2.5 8 42.3 3.7 8.8 7.5 17.7 0.7
A 10 13.0 2.5 19.3 5.0 38.5 10 49.5 2.8 5.7 5.7 11.4
B 10 11.6 1.0 9.0 2.1 18.0 10 48.9 3.8 7.7 7.5 15.4
C 10 5.6 1.8 31.4 3.5 62.8 10 36.1 1.6 4.5 3.2 9.0
Phenol lg/cig 3R4F 9 7.6 0.6 7.9 1.2 15.8 1.9 8 14.7 0.6 4.1 1.2 8.2 2.7 0.5
A 10 14.0 2.4 17.4 4.9 34.8 10 28.5 3.3 11.6 6.6 23.2 0.7
B 10 13.1 1.8 13.5 3.6 27.1 10 27.7 3.3 11.7 6.5 23.5 0.9
C 10 3.8 0.5 13.8 1.1 27.7 10 12.6 1.3 10.1 2.5 20.1 0.7
o-Cresol lg/cig 3R4F 9 2.49 0.18 7.2 0.36 14.4 2.2 8 4.71 0.16 3.4 0.32 6.8 2.9 0.5
A 10 3.71 0.71 19.2 1.43 38.5 10 7.50 0.78 10.4 1.56 20.8 0.5
B 10 3.73 0.58 15.5 1.15 31.0 10 7.64 0.67 8.8 1.34 17.5 0.6
C 10 1.18 0.15 12.7 0.30 25.4 10 3.34 0.35 10.4 0.69 20.8 0.8
m-Cresol lg/cig 3R4F 9 2.09 0.11 5.0 0.21 10.0 3.5 8 3.92 0.30 7.7 0.60 15.4 1.9 1.5
A 10 2.99 0.58 19.4 1.16 38.7 10 6.15 0.96 15.6 1.91 31.1 0.8
B 10 2.93 0.51 17.4 1.02 34.9 10 6.20 0.91 14.7 1.82 29.4 0.8
C 10 1.02 0.16 15.8 0.32 31.6 10 2.89 0.40 13.9 0.80 27.8 0.9
p-Cresol lg/cig 3R4F 9 4.69 0.45 9.6 0.90 19.3 1.8 8 9.40 0.62 6.6 1.23 13.1 2.1 0.7
A 10 7.57 1.42 18.8 2.84 37.6 10 16.07 2.33 14.5 4.65 29.0 0.8
B 10 6.85 1.20 17.4 2.39 34.9 10 14.97 1.98 13.2 3.97 26.5 0.8
C 10 2.41 0.38 15.8 0.76 31.6 10 7.50 0.98 13.1 1.96 26.2 0.8
Catecholb lg/cig 3R4F 9 38.9 4.3 11.1 8.6 22.1 1.0 8 97.7 5.4 5.6 10.9 11.2 1.8 0.5
A 10 54.8 8.7 15.9 17.4 31.7 10 137.0 15.3 11.2 30.6 22.3 0.7
B 10 50.1 4.3 8.6 8.6 17.3 10 124.7 11.6 9.3 23.3 18.7 1.1
C 10 25.0 2.6 10.2 5.1 20.5 10 86.3 8.4 9.7 16.8 19.4 0.9
Resorcinol lg/cig 3R4F 9 0.78 0.11 14.0 0.22 28.0 1.8 8 2.25 0.37 16.3 0.73 32.6 1.0 1.2
A 10 1.39 0.34 24.4 0.68 48.9 10 3.84 0.63 16.4 1.26 32.8 0.7
B 10 1.20 0.31 25.5 0.61 51.0 10 3.45 0.61 17.8 1.23 35.6 0.7
C 10 0.51 0.13 26.1 0.27 52.3 10 2.31 0.36 15.5 0.72 31.0 0.6
Hydroquinoneb lg/cig 3R4F 9 31.1 1.9 6.3 3.9 12.5 2.1 8 86.7 4.9 5.6 9.8 11.3 1.7 0.9
A 10 49.2 8.9 18.0 17.7 36.1 10 125.8 12.3 9.8 24.7 19.6 0.5
B 10 46.3 4.0 8.7 8.0 17.3 10 122.1 13.0 10.6 26.0 21.3 1.2
C 10 21.6 2.6 12.2 5.3 24.3 10 85.2 6.6 7.7 13.2 15.4 0.6
B[a]P Cigarette weight mg/cig 3R4F 9 1037 4 0.4 9 0.8 2.1 7 1075 14 1.3 28 2.6 0.9
A 10 921 8 0.9 17 1.8 10 960 12 1.2 23 2.4
B 10 896 7 0.7 13 1.5 10 936 10 1.1 20 2.1
C 10 839 9 1.0 18 2.1 10 884 12 1.3 23 2.6
Puff No. 3R4F 9 7.9 0.0 0.6 0.1 1.2 3.4 7 10.7 0.2 1.7 0.4 3.4 1.4
A 10 7.9 0.1 1.5 0.2 3.1 10 10.8 0.3 2.6 0.6 5.2
B 10 7.5 0.2 2.2 0.3 4.5 10 10.2 0.2 1.9 0.4 3.8
C 10 7.1 0.2 2.4 0.3 4.8 10 8.8 0.3 2.8 0.5 5.7
TPM mg/cig 3R4F 9 10.3 0.5 4.7 1.0 9.5 1.0 7 45.7 2.2 4.9 4.4 9.7 1.0
A 10 13.5 0.7 4.9 1.3 9.7 10 52.4 2.0 3.9 4.1 7.7
B 10 12.2 0.5 4.1 1.0 8.2 10 50.4 2.2 4.3 4.3 8.6
C 10 5.6 0.3 5.6 0.6 11.2 10 36.4 2.4 6.7 4.9 13.4
B[a]Pb ng/cig 3R4F 9 6.22 0.29 4.6 0.57 9.2 1.5 7 13.59 0.69 5.1 1.38 10.1 1.0 1.1
A 10 8.03 0.62 7.8 1.25 15.5 10 17.27 1.02 5.9 2.05 11.8 0.8
B 10 7.00 0.45 6.4 0.90 12.9 10 15.73 0.81 5.2 1.62 10.3 0.8
C 10 4.43 0.30 6.8 0.61 13.7 10 13.04 0.61 4.7 1.23 9.4 0.7
HCN Cigarette weight mg/cig 3R4F 9 1036 5 0.5 10 0.9 2.7 10 1073 7 0.6 14 1.3 2.2
A 10 919 11 1.2 21 2.3 10 963 18 1.9 37 3.8
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B 10 891 14 1.6 28 3.1 10 936 8 0.8 16 1.7
C 10 844 8 1.0 17 2.0 10 888 13 1.5 27 3.0
Puff No. 3R4F 9 8.8 0.1 1.4 0.2 2.8 2.0 10 10.7 0.3 2.4 0.5 4.7 1.1
A 10 8.7 0.2 2.5 0.4 4.9 10 11.1 0.4 3.9 0.9 7.8
B 10 8.2 0.2 2.7 0.4 5.5 10 10.3 0.3 2.5 0.5 5.0
C 10 7.8 0.2 3.1 0.5 6.3 10 8.9 0.1 1.7 0.3 3.3
HCNb lg/cig 3R4F 9 104.7 7.1 6.8 14.3 13.7 2.4 10 392.3 19.9 5.1 39.8 10.1 1.6 0.7
A 10 106.9 16.1 15.0 32.2 30.1 10 381.1 42.4 11.1 84.8 22.2 0.7
B 10 86.9 13.6 15.7 27.2 31.3 10 328.7 19.1 5.8 38.3 11.6 0.4
C 10 37.4 6.9 18.3 13.7 36.6 10 338.9 26.4 7.8 52.8 15.6 0.4
Ammonium ion Cigarette weight mg/cig 3R4F 9 1037 4 0.4 8 0.8 1.9 10 1074 12 1.1 24 2.2 1.1
A 10 922 10 1.1 21 2.3 10 960 10 1.1 21 2.1
B 10 897 6 0.7 13 1.4 10 935 12 1.3 24 2.6
C 10 840 4 0.5 8 1.0 10 884 10 1.1 20 2.3
Puff No. 3R4F 9 8.4 0.2 2.2 0.4 4.4 1.3 10 10.5 0.2 2.1 0.4 4.2 1.6
A 10 8.3 0.2 2.7 0.4 5.4 10 10.7 0.4 4.0 0.9 8.1
B 10 7.9 0.2 2.8 0.4 5.5 10 10.0 0.3 3.2 0.6 6.5
C 10 7.5 0.2 3.1 0.5 6.2 10 8.9 0.3 3.0 0.5 6.1
Ammonium ionb 3R4F 9 7.9 0.4 5.5 0.9 11.0 1.1 10 29.8 0.9 3.1 1.9 6.3 2.2 0.6
A 10 10.2 0.6 6.0 1.2 12.0 10 42.8 4.1 9.6 8.2 19.1 1.6
B 10 9.2 0.6 6.5 1.2 13.0 10 36.0 1.9 5.2 3.7 10.4 0.8
C 10 4.2 0.2 5.2 0.4 10.4 10 28.0 1.7 6.2 3.5 12.4 1.2
Semi volatiles Cigarette weight mg/cig 3R4F 9 1038 4 0.4 8 0.7 2.0 8 1053 16 1.5 32 3.0 0.7
A 10 919 8 0.9 17 1.8 10 959 10 1.0 19 2.0
B 10 893 6 0.7 13 1.4 10 934 7 0.8 15 1.6
C 10 839 4 0.5 9 1.1 10 887 11 1.2 21 2.4
Puff No. 3R4F 9 8.3 0.2 2.0 0.3 4.1 0.9 8 10.5 0.5 4.5 1.0 9.1 0.7
A 10 8.3 0.2 2.7 0.5 5.5 10 10.8 0.3 2.9 0.6 5.7
B 10 8.0 0.1 1.6 0.3 3.2 10 10.0 0.3 3.2 0.6 6.3
C 10 7.6 0.1 1.4 0.2 2.8 10 8.9 0.3 3.9 0.7 7.8
TPM mg/cig 3R4F 9 10.0 0.5 4.9 1.0 9.9 0.9 8 43.6 1.2 2.8 2.4 5.6 1.6
A 10 13.7 0.5 3.9 1.1 7.8 10 51.8 2.1 4.1 4.2 8.2
B 10 12.4 0.7 5.7 1.4 11.3 10 48.3 1.9 3.9 3.8 7.9
C 10 5.4 0.2 4.0 0.4 7.9 10 34.9 1.9 5.4 3.8 10.8
Pyridine lg/cig 3R4F 9 4.5 0.6 13.9 1.3 27.9 1.2 8 32.5 4.3 13.1 8.5 26.2 1.0 0.9
A 10 8.0 1.3 16.6 2.6 33.2 10 40.2 4.6 11.4 9.2 22.8 0.7
B 10 7.3 1.2 16.6 2.4 33.1 10 33.2 3.5 10.5 6.9 20.9 0.6
C 10 2.9 0.5 18.4 1.1 36.8 10 25.4 4.0 15.8 8.0 31.6 0.9
Quinoline lg/cig 3R4F 9 0.27 0.03 12.5 0.07 25.0 1.5 8 0.47 0.06 12.2 0.11 24.4 0.8 1.0
A 10 0.43 0.07 15.9 0.14 31.8 10 0.75 0.06 8.6 0.13 17.3 0.5
B 10 0.44 0.08 18.1 0.16 36.3 10 0.71 0.06 8.8 0.13 17.7 0.5
C 10 0.15 0.04 22.7 0.07 45.3 10 0.43 0.05 12.0 0.10 24.0 0.5
Styrene lg/cig 3R4F 9 4.2 0.5 12.5 1.1 25.0 1.0 8 16.7 1.7 10.1 3.4 20.2 1.2 0.8
A 10 6.0 0.7 12.2 1.5 24.5 10 20.0 1.9 9.6 3.9 19.3 0.8
B 10 5.4 0.5 8.9 1.0 17.7 10 17.1 2.0 11.6 4.0 23.2 1.3
C 10 2.7 0.4 15.0 0.8 30.0 10 15.0 2.2 14.7 4.4 29.4 1.0
Metals Cigarette weight mg/cig 3R4F 10 1042 3 0.3 7 0.6 2.4 12 1086 5 0.5 11 1.0 2.7
A 10 926 9 0.9 18 1.9 10 966 10 1.0 19 2.0
B 10 900 9 1.0 18 2.0 10 941 13 1.4 26 2.8
C 10 846 3 0.4 7 0.8 10 889 15 1.7 30 3.3
Puff No. 3R4F 10 8.2 0.1 1.4 0.2 2.8 2.1 12 10.6 0.2 1.5 0.3 3.0 1.5
A 10 8.1 0.2 2.5 0.4 5.0 10 10.7 0.3 3.1 0.7 6.2
B 10 7.9 0.2 2.0 0.3 4.1 10 10.2 0.2 2.1 0.4 4.1
C 10 7.5 0.3 4.0 0.6 8.0 10 8.6 0.1 1.7 0.3 3.5
Arsenic ng/cig 3R4F 10 <2.7 12 12.2 1.1 9.0 2.2 18.0 3.7
A 10 2.7 10 9.6 3.6 38.0 7.3 75.9
B 10 2.8 10 <8.8 2.5 28.9 5.0 57.8
(continued on next page)
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Table 3 (continued)
Analysis Analyte Units Product ISO smoking regime HCI smoking regime HCI CV/ISO
CV
No.
samples
Mean SD CV
(%)
2 SD 2 CV
(%)
CV
ratioa
No.
samples
Mean SD CV
(%)
2 SD 2 CV
(%)
CV
ratioa
C 10 <2.7 10 <8.8
Cadmiumb ng/cig 3R4F 10 29.8 1.7 5.8 3.5 11.6 2.2 12 108.6 5.9 5.4 11.8 10.9 1.9 0.9
A 10 30.0 5.1 16.9 10.2 33.9 10 96.7 11.3 11.7 22.7 23.4 0.7
B 10 29.1 2.5 8.6 5.0 17.2 10 92.9 6.7 7.2 13.4 14.5 0.8
C 10 13.2 1.6 12.0 3.2 24.0 10 77.8 9.7 12.5 19.4 24.9 1.0
Chromium ng/cig 3R4F 10 <3.7 12 <14.0
A 10 <3.7 10 <14.0
B 10 <3.7 10 <14.0
C 10 <3.7 10 <14.0
Mercury ng/cig 3R4F 10 <1.1 12 5.2 0.3 5.6 0.6 11.2
A 10 <1.1 10 <4.2
B 10 <1.1 10 <4.2
C 10 <1.1 10 <4.2
Nickel ng/cig 3R4F 10 <30.9 12 <25.5
A 10 <30.9 10 <25.5
B 10 <30.9 10 <25.5
C 10 <30.9 10 <25.5
Lead ng/cig 3R4F 10 <10.3 12 34.4 4.3 12.6 8.7 25.2 0.9
A 10 11.0 10 33.3 3.5 10.5 7.0 20.9
B 10 12.7 10 35.2 3.2 9.0 6.3 18.0
C 10 <10.3 10 26.3 3.8 14.3 7.5 28.7
Selenium ng/cig 3R4F 10 <2.3 12 <15.6
A 10 <2.3 10 <15.6
B 10 <2.3 10 <15.6
C 10 <2.3 10 <15.6
Nitrogen oxides Puff No. 3R4F 9 8.2 0.2 1.9 0.3 3.7 1.3 9 10.3 0.2 2.3 0.5 4.6 0.9
A 10 8.2 0.2 1.9 0.3 3.8 10 10.7 0.2 2.2 0.5 4.3
B 10 8.0 0.1 1.4 0.2 2.8 10 10.2 0.3 2.5 0.5 5.0
C 10 7.4 0.3 3.7 0.6 7.5 10 8.7 0.1 1.3 0.2 2.5
NO lg/cig 3R4F 9 206 17 8.0 33 16.0 1.1 9 540 20 3.7 40 7.3 1.7 0.5
A 10 153 17 11.0 34 22.0 10 375 28 7.4 56 14.8 0.7
B 10 135 12 9.1 24 18.1 10 351 15 4.3 30 8.7 0.5
C 10 90 6 6.8 12 13.6 10 328 22 6.6 43 13.2 1.0
NOxb lg/cig 3R4F 9 228 12 5.5 25 10.9 1.3 9 608 28 4.5 55 9.1 1.3 0.8
A 10 169 12 7.3 25 14.6 10 433 33 7.6 66 15.3 1.0
B 10 151 10 6.9 21 13.7 10 414 18 4.3 35 8.5 0.6
C 10 99 7 6.7 13 13.5 10 384 21 5.5 42 10.9 0.8
a CV ratio = mean CV commercial product/CV 3R4F.
b Smoke toxicants of regulatory relevance (Table 1).
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Table 4
Monthly variation in emission levels of mainstream smoke toxicants as a ratio to nicotine.
Toxicant Unit per mg nicotine Product HCI data as a ratio to nicotine
Sample No. Mean SD CV (%) 2CV (%) CV ratioa
TPM mg 3R4F 7 22.3 0.6 2.5 5.0 1.5
A 10 22.2 0.6 2.7 5.5
B 10 22.7 0.8 3.5 7.0
C 10 22.7 1.1 5.0 10.0
NNK ng 3R4F 9 157.6 14.7 9.3 18.6 1.8
A 10 56.4 12.4 22.0 44.1
B 10 71.5 11.7 16.4 32.8
C 10 50.2 6.0 12.0 24.1
NNN ng 3R4F 9 158.7 12.0 7.6 15.1 2.1
A 10 141.7 27.2 19.2 38.4
B 10 77.1 8.8 11.3 22.7
C 10 138.7 23.7 17.1 34.2
Acetaldehyde lg 3R4F 10 627 28 4.5 9.1 1.6
A 10 468 28 6.0 12.0
B 10 520 30 5.8 11.6
C 10 626 62 9.9 19.7
Acrolein lg 3R4F 10 63.5 4.8 7.6 15.1 1.0
A 10 48.8 3.6 7.4 14.8
B 10 56.8 3.7 6.5 12.9
C 10 64.3 6.2 9.7 19.3
Acrylonitrile lg 3R4F 8 17.1 0.9 5.3 10.7 1.8
A 10 16.1 1.2 7.6 15.2
B 10 15.2 1.4 9.1 18.2
C 10 21.1 2.4 11.3 22.7
4-ABP ng 3R4F 7 1.4 0.1 3.9 7.9 2.2
A 10 1.6 0.1 7.9 15.7
B 10 1.4 0.1 8.1 16.3
C 10 1.7 0.2 9.9 19.9
1-AN ng 3R4F 7 11.6 0.6 4.9 9.8 1.5
A 10 12.7 1.0 7.7 15.5
B 10 12.5 1.1 8.8 17.6
C 10 12.1 0.7 5.9 11.8
2-AN ng 3R4F 7 6.8 0.3 3.9 7.7 1.6
A 10 7.1 0.5 6.5 13.0
B 10 6.9 0.5 7.2 14.5
C 10 7.0 0.4 5.0 10.0
Ammonium ion lg 3R4F 10 15.2 0.7 4.6 9.3 1.6
A 10 18.4 1.6 8.8 17.6
B 10 16.9 0.9 5.4 10.7
C 10 18.0 1.4 7.6 15.1
Benzene lg 3R4F 8 50.4 3.6 7.1 14.2 1.2
A 10 42.3 3.2 7.6 15.2
B 10 40.8 3.2 7.9 15.7
C 10 53.7 5.3 9.9 19.7
B[a]P ng 3R4F 7 6.89 0.44 6.4 12.7 0.9
A 10 7.42 0.50 6.8 13.5
B 10 7.40 0.42 5.7 11.4
C 10 8.37 0.43 5.2 10.3
1,3-Butadiene lg 3R4F 8 46.0 13.3 28.8 57.7 0.8
A 10 38.9 9.2 23.5 47.1
B 10 38.1 8.6 22.7 45.4
C 10 52.1 11.8 22.7 45.4
Cadmium ng 3R4F 12 55.3 3.0 5.4 10.7 2.0
A 10 41.4 3.9 9.4 18.8
B 10 43.7 3.6 8.2 16.4
C 10 50.0 6.9 13.9 27.8
CO mg 3R4F 7 15.8 0.5 3.3 6.7 1.3
A 10 11.5 0.4 3.5 6.9
B 10 12.3 0.4 3.1 6.2
C 10 14.8 0.9 6.2 12.3
Catechol lg 3R4F 8 49.7 3.2 6.5 13.0 1.4
A 10 58.7 5.7 9.7 19.5
B 10 58.7 5.3 9.0 17.9
C 10 55.4 5.0 9.1 18.2
Crotonaldehyde lg 3R4F 10 23.6 2.0 8.5 17.1 1.2
A 10 19.9 1.8 9.2 18.5
(continued on next page)
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Table 4 (continued)
Toxicant Unit per mg nicotine Product HCI data as a ratio to nicotine
Sample No. Mean SD CV (%) 2CV (%) CV ratioa
B 10 22.2 1.8 7.9 15.8
C 10 24.4 3.1 12.8 25.5
Formaldehyde lg 3R4F 10 36.7 3.3 9.1 18.2 1.5
A 10 28.2 2.9 10.3 20.6
B 10 43.7 6.0 13.7 27.5
C 10 30.1 4.9 16.2 32.4
HCN lg 3R4F 10 199 8 4.1 8.2 2.5
A 10 164 21 12.6 25.2
B 10 155 12 7.7 15.4
C 10 218 24 11.0 22.0
Hydroquinone lg 3R4F 8 44.1 2.6 6.0 12.0 1.4
A 10 54.0 4.8 9.0 18.0
B 10 57.3 4.9 8.6 17.2
C 10 54.7 4.1 7.5 15.1
Isoprene lg 3R4F 8 530 45 8.6 17.1 0.9
A 10 435 37 8.5 17.0
B 10 434 32 7.4 14.7
C 10 559 43 7.6 15.2
NOx lg 3R4F 9 308 16 5.2 10.5 1.5
A 10 186 15 8.1 16.1
B 10 195 12 5.9 11.9
C 10 247 22 8.9 17.7
Toluene lg 3R4F 8 83.3 4.5 5.4 10.8 1.0
A 10 71.3 4.5 6.2 12.5
B 10 66.9 2.5 3.7 7.4
C 10 83.1 5.4 6.5 13.1
a CV ratio = mean CV commercial product/CV 3R4F.
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few toxicants present at the ng/g or ng/cigarette (i.e. ppb) level,
however, variation was 20% or even higher. The sources of this var-
iation may be analytical in origin or may derive from the products
themselves. These two sources will contribute to every measure-
ment, but the relative magnitudes remain to be established.
4.1. Analytical variation including sample preparation
Factors affecting the variability of an analytical method include
preparation of the sample, the amount of analyte measured, and
the complexity of the analysismethod. The effects of all of these fac-
tors together are reﬂected in the ﬁnding that nicotine and CO emis-
sions, which were measured at milligram per cigarette (mg/cig)
levels after a simple sample extraction, showedmuch less variation
(mean CV 6 7%) as compared with tobacco-speciﬁc nitrosamine
(TSNA) emissions, whichwere determined at nanogramper cigaret-
te (ng/cig) levels and required amore complex sample clean-up pro-
cedure (mean CV < 30%). This is in keeping with the observations of
Horwitz et al. (1980) who demonstrated that the relative standard
deviation for an analyte increases exponentially as its concentration
decreases, regardless of the analyte being measured.
In the present study, most of the toxicants were measured by
multi-analyte methods. Comparison of the variation among toxi-
cants within a single analysis highlighted some with relatively high
variation as compared with others within the same analysis. For
example, in the analysis of carbonyl emissions, both crotonaldehy-
de (12.5%) and formaldehyde (10.9%) showed notably more varia-
tion than acetaldehyde (6.8%) under ISO conditions, and it is likely
that the 10-fold higher level of acetaldehyde measured contributes
signiﬁcantly to this lower level of variation.
4.1.1. Variation due to smoke sample preparation
For each toxicant analysis, the weight of the cigarette used, the
puff number and the TPM were also recorded to enable an estima-
tion of the variation due to preparation of the smoke sample itself.These data document the build-up of variation from the product
through the smoking process to the ﬁnal preparation for toxicant
analysis. In the analysis of NNK in mainstream smoke, for example,
the variation in product is represented by the cigarette weight CV,
the variation in the smoking process by the puff number CV, and
the variation in the ﬁnal preparation for toxicant analysis by the
TPM CV. Fig. 1 shows that CV increased steadily across these attri-
butes, giving a practical lower limit of variation for a relatively con-
trolled analysis. Fig. 1 also shows the variation in levels of NNK in
the cigarette ﬁller blend and demonstrates that the variation in the
ﬁller blend is also a signiﬁcant driver of the variation of NNK emis-
sions in the smoke. This is true for other toxicants present in the
ﬁller blend, including NNN, B[a]P and cadmium (see Supplemen-
tary Figures, which also includes a ﬁgure for benzene for compar-
ison as an analyte which is not present in the cigarette ﬁller blend).
Wewould not expect the variation observed in the ﬁnal toxicant
analysis to be less than that observed in the ﬁnal preparation of
smoke for toxicant analysis; therefore, we would not expect varia-
tion in smoke emissions from a single product to be less than the
variation in TPM. Variation in TPM measurements in the present
studywere typically 3–6% CV under both ISO and HCI regimes, indi-
cating the lower limit of practical variability. Furthermore, if a tox-
icant is present in the ﬁller blend and can readily distil to the smoke,
then variation in its levels in the ﬁller blend will contribute to the
overall variation observed in the emissions of that toxicant. This also
holds if the precursor of a toxicant varies in the ﬁller blend.
4.1.2. Variation due to smoking regime
Current and proposed regulations formeasurement and reporting
ormandated lowering of smoke toxicant levels require data generat-
ed at various regimes, for example: in Brazil, ANVISA require mea-
surement and reporting under the ISO smoking regime (Brazil
Resolution, 2007); in the US, the FDA require measurement and
reporting under both ISO and an intense (HCI) regime (FDA, 2012b),
whilst the TobReg propose mandated lowering of toxicants when
determined as a ratio to nicotine under HCI regime (WHO, 2008).
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Fig. 1. Coefﬁcients of variation for various aspects of NNK analysis.
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ed toxicant ceilings under the HCI regime is that variation (CV) for
the determination of NNK and NNN is less when these toxicant
emissions are determined under HCI than when determined under
ISO conditions. In this study, the CV for NNK determined under HCI
conditions was 10% lower than when determined under ISO condi-
tions for all 3 commercial products. However for NNN the results
were mixed (Table 3). B[a]P and CO variation was also less for all
three commercial products determined under HCI compared to
ISO, whilst variation in nicotine, formaldehyde, acetaldehyde, acro-
lein and benzene under the two regimes were mixed. Results for
1,3-butadiene determined under HCI were noticeably more vari-
able than when determined under ISO due to analytical variability,
as discussed in Section 4.1.3.
4.1.3. Variation due to analytical method
In the analysis of volatile compound emissions from products
smoked under HCI conditions, benzene and 1,3-butadiene had
average CVs of 6.1% and 20.9%, respectively. Both toxicants were
measured in the same analysis and similar levels of each toxicant
(100 lg/cig) were found in smoke (Fig. 2). This is an example of
an issue with the analytical method whereby the 1,3-butadieneFig. 2. Variation in monthly sample results for two volatile toxicants (1,3-butadiene a
analytical batches because more than one monthly sample of product was analysed in a
sample of product B was analysed in a different batch (batch F) to products A and C (Baresults showed a synchronous pattern of variation across all four
products (the three commercial cigarettes and 3R4F). Due to the
different manufacturing histories of the four cigarettes, these tem-
poral trends clearly indicate that the additional variability in 1,3-
butadiene results, when determined under HCI conditions, was
analytical in origin. This is potentially due to the higher volatility
of 1,3-butadiene compared to benzene and suggests that there
may be scope for improvement in the analytical method for this
analyte in this laboratory.
This was the most striking example of the inﬂuence of analyti-
cal variation. Less pronounced examples of synchronous trends
were observed, particularly where results were around the quanti-
tation limits of the method, for example some of the minor nico-
tine alkaloids.
4.2. Product variation
Variations in the absolute levels of toxicants would be expected
among products due to differences in product design and blend
composition. It was known that the design and blend recipe of
the BAT products (A and C) did not change during the course of this
study (this aspect was unknown for product B, although ournd benzene) under HCI conditions. For this analysis, there were 8 rather than 10
single analytical batch on two occasions (analysis batch A and F). Also one monthly
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Fig. 3. Product variation in ﬁller blend content and emission of NNN, showing
variation related to month of sampling. Data for 3R4F data are plotted at a single
undeﬁned time-point, reﬂecting the provenance of these reference samples. The
shaded area indicates the maximum variation in 3R4F data; data lying outside this
region indicate that variation in the commercial products exceeds that in the 3R4F
monitor cigarette.
424 A. Eldridge et al. / Regulatory Toxicology and Pharmacology 71 (2015) 409–427analyses did not indicate any step change in product performance
and levels of variability were similar to products A and C); never-
theless, variation might arise from factors such as the blending of
tobacco grades that make up the cigarette ﬁller blend, from the
multiple sources of these grades over time, and from the multiple
manufacturing operations, as well as from the inherent variation in
the tobacco leaves themselves, tobacco being a natural product.
As an example, the blend contents and emission data for NNN, a
TSNA that is readily transferred from the tobacco blend to the
smoke during the combustion process, over the 10-month study
period are shown for the four products in Fig. 3. To aid comparison,
the NNN levels were normalised to the mean for each product to
achieve a uniform scale across the three sets of data (blend, ISO
and HCI). For the individual commercial products, the blend, ISO
and HCI data showed similar trends over time: these trends
demonstrate the variability of each commercial product over time.
Notably, products A and C showed variation in the NNN levels of
the monthly product samples that was greater than that of the
3R4F monitor (Fig. 3, shaded region).
The additional variation in commercial products for each ana-
lyte, due to manufacturing and compositional variation, can beFig. 4. CV ratio of all results vequantiﬁed by calculating the CV ratio (average CV of the commer-
cial products to CV of 3R4F), based on the view that the variation in
3R4F is a measure of the repeatability of the method (i.e. the small-
est level of reference variability that can be obtained with a
cigarette product). A ratio of greater than 1 indicates that the vari-
ability in the commercial products over time is greater than the
repeatability of the method.
As shown in Tables 2 and 3, the CV ratio averaged 1.7 for blend
components, 1.5 for smoke emissions determined under the HCI
regime, and 1.7 for smoke emissions determined under the ISO
regime. Some toxicants such as 1,3-butadiene had a ratio of less
than 1.0 (0.8 under ISO conditions, 0.7 under HCI conditions), indi-
cating that analytical variability was greater than the variability
induced by multiple manufacturing batches for this toxicant.
For several toxicants, the CV ratio was higher, between 2.0 and
3.5, indicating a greater degree ofmonthly variation in the commer-
cial product as compared with 3R4F. This was true for total and
reducing sugars, chlorogenic acid and cadmium in ﬁller blend; nico-
tine, NNN, NNK, NAT, o- and p-cresol, hydroquinone, HCN and cad-
mium emissions under ISO conditions; 2-AN, 4-ABP, phenol, o- and
p-cresol, arsenic and butyraldehyde under HCI conditions; and
NNN, 4-ABP and HCN when determined as a ratio to nicotine under
HCI conditions. All of these toxicants, with the exception of total
sugars, reducing sugars and chlorogenic acid, were present at levels
below 1000 ppm (Fig. 4), which may in part contribute to the
greater variation. ‘Total’ and ‘reducing’ sugars are a collective term
for a range of species determined colorimetrically by the current
methods, rather than a speciﬁc chemical reaction, and therefore
the results are likely to be more variable than for other more speci-
ﬁc analyses. However the CV ratio demonstrates greater variability
for total and reducing sugars in the commercial products, compared
to 3R4F, which can only be due to product variability i.e. a combina-
tion of ﬂuctuations in levels of sugars in the tobacco grades and the
effects of curing on those initial sugar levels, similarly for chloro-
genic acid. The high butyraldehyde CV ratio (5.8 under the HCI
regime) is likely to be due to the atypically low variation in 3R4F
(CV 2.6%) because the average CV for the commercial products
was similar to that achieved under ISO smoking conditions.
4.3. Variation in toxicant emission levels as a ratio to nicotine
The TobReg recommendations include establishing levels for
selected toxicant emissions per mg of nicotine, measured underReducing 
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Fig. 5. Potential error associated with single-point-in-time analysis of toxicants of regulatory interest for commercial, high-volume cigarette products: (a) ﬁller blend
components, (b) toxicant emissions under ISO regime, (c) toxicant emissions under HCI regime. The dotted black line shows the median value for each of the 3 categories.
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above these levels (WHO, 2008). As summarised by Burns et al.
(2008), the aim of comparing toxicant levels to nicotine is to shift
the interpretation of the measurement away from the amount of
smoke generated per cigarette and towards characterisation of
smoke toxicity generated under standardised conditions.
Importantly, toxicant emission levels can be reported as a ratio
to nicotine only via calculation based on the mean data per sample
(i.e. toxicant mean divided by nicotine mean) because analysis of
nicotine is done separately (i.e. using a different cigarette, and a
different number of replicates) from that of most toxicants, CO
being the exception. As a result, the calculation cannot take into
account the variation in the individual replicates within each sam-
ple result.
When the current data were expressed as a ratio to nicotine, the
variation in the data for the 9 toxicants mandated for lowering by
TobReg tended to increase by 1–2 percentage points as compared
with the absolute values (Tables 3 and 4), although for a few of
the 23 toxicants (aromatic amines, phenols and cadmium), there
was a small decrease in variability. This is not surprising because
there is inherent product and analytical variability in each of the
two measurements (toxicant and nicotine emission), and combin-
ing the data should in theory lead to an increase in the variability
observed as the measurement error for each compound is com-bined. Even analysis of CO, which was performed on the same
cigarette as nicotine, tended to show an increase in variation
between the absolute values and the CO/nicotine ratio (from 0.0%
to 4.2%), owing to the combined errors in analytical measurement.
The TPM to nicotine data, calculated using the TNCO TPM, which
was subsequently analysed for nicotine emissions, illustrates the
potential decrease in variation achievable when a paired analysis
is conducted (Tables 3 and 4).
Related to this, Cahours et al. (2013) noted that, owing to use of
different (unpaired) cigarettes for nicotine analysis versus other
toxicant analyses, ISO methods could not provide a robust estimate
of repeatability and reproducibility for nicotine ratio analysis (ISO,
1994), thus questioning the accuracy of this method of reporting
emissions data.
4.4. Tolerance levels and indications for product regulation
For an analyte, the value of 2SD can be calculated as an
approximation of 95% conﬁdence intervals, thereby indicating the
range of values that might be reported for a single large-volume
commercial product over time when measured in a single labora-
tory. Stated as a percentage (2CV), this kind of variability or ‘‘toler-
ance’’ has been recognised in the regulatory reporting of TNCO
when determined under the ISO regime, where a tolerance of
426 A. Eldridge et al. / Regulatory Toxicology and Pharmacology 71 (2015) 409–427±15% for tar and nicotine reporting and ±20% for CO reporting are
applicable with repeated sampling (ISO, 2013). The maximum 2CV
values for TNCO determined in this single-centre study under ISO
were 14.4%. If closer to 100% coverage of data were required, then
an interval of 3SD (99.7%, empirically) would be more appropriate;
and, if measurements were carried out at more than one laborato-
ry, then inter-laboratory variation would also need to be taken into
account, again increasing the interval substantially (Intorp et al.,
2009; Teillet et al., 2013).
Considering all of the results for the commercial products in the
present study (i.e. tobacco blend, and smoke emissions determined
under either smoking regime and when expressed as a ratio to
nicotine), 2CV values averaged 20% (Tables 2–4). However, the
2CV value reached in excess of 50% for some low-level toxicants,
where the levels were near to the quantitation limits of the analy-
tical method.
These 2CV values demonstrate the uncertainty and therefore
the potential error associated with a single-point-in-time sample
of a high-volume commercial cigarette product in a single labora-
tory. Fig. 5 summarises these ﬁndings for the toxicants of regulato-
ry interest deﬁned in Table 1 and shows the median 2CV value for
all toxicant measurements in each category: 19.4% for ﬁller blend
components, 19.5% for toxicant emissions under ISO, 17.8% for tox-
icant emissions under HCI.
This suggests that tolerances higher than those currently appli-
cable to TNCO analysis under the ISO regime would be advisable
for many of these smoke toxicants, should proposed ceilings be
enacted.5. Conclusions
Cigarette smoke toxicants have become a global regulatory
issue, with mandatory reporting of smoke toxicant emission levels
and cigarette ﬁller blend components in several countries, and pro-
posals for further regulation including toxicant ceilings for emis-
sions and/or ﬁller blend components. Against this background, an
understanding of variation is essential.
Here, the monthly variation in toxicant emissions from smoke
and blend toxicants evaluated in a single laboratory was found to
be less than 15% CV for many toxicants, but considerably higher
for others, particularly those at the nanogram per gram (ppb) level.
For some toxicants such as 1,3-butadiene (CV < 28%), the source of
the variation was clearly analytical, indicating that it might be nec-
essary to improve the accuracy of the analytical methods before
standardised regulatory reporting might be achieved. As compared
with the 3R4F reference cigarette, the 10-month variability in
blend components, ISO and HCI toxicant emissions was 50–70%
higher for the commercial cigarettes. Because the 3R4F reference
was manufactured in a single batch, these values provide an esti-
mate of the long-term variation due to natural ﬂuctuations in the
tobacco blend and adjustments in the manufacturing process.
This study has demonstrated the uncertainty around measured
levels of toxicants in three high-volume commercial cigarettes and
therefore the potential error which might be associated with sin-
gle-point-in-time sampling of these products. Deﬁned as 2CV, this
potential error averaged 20% but was approaching 50% for some
low level toxicants.
It is important to stress that these values are for a single labora-
tory. Repeated measures across more than one laboratory will
increase the variability substantially (Gregg et al., 2004. Intorp
et al., 2009). Taken together, the present results demonstrate the
importance of taking all sources of variation into account when
mandating maximum product levels of toxicants and analytical
tolerance limits.Conﬂict of interest
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